Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision ...
HELSINKI, Dec 12 (Reuters) - The European Medicines Agency (EMA) will allow Novo Nordisk (NOVOb.CO), opens new tab to add risk reduction for events related to kidney disease to the label of its ...
On Thursday, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for an update for Novo Nordisk A/S’ (NYSE:NVO) Ozempic (once-weekly subcutaneous ...
(RTTNews) - Novo Nordisk A/S (NVO), Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug ...
Sept 1 (Reuters) - U.S. health regulators on Thursday approved a label update to Novartis AG's osteoporosis drug Reclast to warn about the risk of kidney failure associated with the use of the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results